文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

复发模式对再次手术治疗复发性胶质母细胞瘤患者的影响。

Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma.

机构信息

Radiation Oncology Unit, Pisa University Hospital, Via Roma 67, 56123, Pisa, Italy.

Neurosurgery Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

出版信息

Acta Neurol Belg. 2022 Apr;122(2):441-446. doi: 10.1007/s13760-021-01765-4. Epub 2021 Aug 16.


DOI:10.1007/s13760-021-01765-4
PMID:34396487
Abstract

The impact of different patterns of glioblastoma (GBM) recurrence has not yet been fully established in patients suitable for a second surgery. Through the present observational study carried out at Pisa University Hospital, we aimed to investigate how different patterns of GBM failure influence second surgery outcomes. Overall survival (OS) and post-recurrence survival (PRS) were assessed according to clinical characteristics, including pattern of recurrence, in a prospective cohort of recurrent GBM patients. Survival curves were calculated using the Kaplan-Meier method and the log-rank test was applied to evaluate the differences between curves. Patients with local recurrence had better OS than patients with non-local one, 24.1 versus 18.2 months, respectively [P = 0.015, HR = 1.856 (1.130-3.050)]. The second surgery conferred an advantage in OS respect to non-operated patients, however, this advantage was more evident in patients with local recurrence [P = 0.002 with HR 0.212 (95% CI 0.081-0.552) and P = 0.029 with HR = 0.522 (95% CI 0.291-0.936), respectively]. The recurrence pattern can influence the outcome of patients with recurrent GBM suitable for a second surgery.

摘要

不同模式的胶质母细胞瘤(GBM)复发对适合二次手术的患者的影响尚未完全确定。通过比萨大学医院进行的这项观察性研究,我们旨在研究不同的 GBM 失败模式如何影响二次手术的结果。根据临床特征,包括复发模式,在复发性 GBM 患者的前瞻性队列中评估总生存期(OS)和复发后生存期(PRS)。使用 Kaplan-Meier 方法计算生存曲线,并应用对数秩检验评估曲线之间的差异。局部复发患者的 OS 优于非局部复发患者,分别为 24.1 个月和 18.2 个月[P=0.015,HR=1.856(1.130-3.050)]。与未手术患者相比,二次手术在 OS 方面具有优势,但这种优势在局部复发患者中更为明显[P=0.002,HR=0.212(95%CI 0.081-0.552)和 P=0.029,HR=0.522(95%CI 0.291-0.936)]。复发模式会影响适合二次手术的复发性 GBM 患者的结局。

相似文献

[1]
Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma.

Acta Neurol Belg. 2022-4

[2]
Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.

Clin Neurol Neurosurg. 2021-8

[3]
Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.

J Neurooncol. 2014-3

[4]
Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.

Neuro Oncol. 2016-4

[5]
Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

J Neurosurg. 2012-10-5

[6]
Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study.

J Neurooncol. 2018-1-2

[7]
Assessing the efficacy of repeat resections in recurrent glioblastoma: a systematic review.

Neurosurg Rev. 2021-6

[8]
Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.

Clin Neurol Neurosurg. 2020-1

[9]
Repeat-surgery at Glioblastoma recurrence, when and why to operate?

Clin Neurol Neurosurg. 2015-9

[10]
Aggressive repeat surgery for focally recurrent primary glioblastoma: outcomes and theoretical framework.

Neurosurg Focus. 2015-3

引用本文的文献

[1]
Liquid biopsy in breast cancer: Redefining precision medicine.

J Liq Biopsy. 2025-7-16

[2]
A Journey into the Complexity of Temporo-Insular Gliomas: Case Report and Literature Review.

Curr Oncol. 2025-1-14

[3]
Local therapy in glioma: An evolving paradigm from history to horizons (Review).

Oncol Lett. 2024-7-17

[4]
Second surgery for relapsed glioblastoma: an observational study on criteria for patient selection in real life.

Future Oncol. 2024

[5]
Cell-Free miRNAs as Non-Invasive Biomarkers in Brain Tumors.

Diagnostics (Basel). 2023-9-8

[6]
Preoperative vascular heterogeneity based on dynamic susceptibility contrast MRI in predicting spatial pattern of locally recurrent high-grade gliomas.

Eur Radiol. 2024-3

[7]
Macrophages in Recurrent Glioblastoma as a Prognostic Factor in the Synergistic System of the Tumor Microenvironment.

Neurol Int. 2023-4-23

[8]
The Prognostic Impact of Gender, Therapeutic Strategies, Molecular Background, and Tumor-Infiltrating Lymphocytes in Glioblastoma: A Still Unsolved Jigsaw.

Genes (Basel). 2023-2-15

[9]
Upstaging and Downstaging in Gliomas-Clinical Implications for the Fifth Edition of the World Health Organization Classification of Tumors of the Central Nervous System.

Diagnostics (Basel). 2023-1-5

[10]
Impact of fractionated stereotactic radiotherapy on activity of daily living and performance status in progressive/recurrent glioblastoma: a retrospective study.

Radiat Oncol. 2022-12-6

本文引用的文献

[1]
Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.

Clin Neurol Neurosurg. 2021-8

[2]
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

Nat Rev Clin Oncol. 2021-3

[3]
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Neuro Oncol. 2020-8-17

[4]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Neuro Oncol. 2019-11-1

[5]
A Meta-Analysis of Survival Outcomes Following Reoperation in Recurrent Glioblastoma: Time to Consider the Timing of Reoperation.

Front Neurol. 2019-3-26

[6]
NRG brain tumor specialists consensus guidelines for glioblastoma contouring.

J Neurooncol. 2019-3-19

[7]
Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).

J Neurooncol. 2018-12-4

[8]
Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early Delayed Administration.

Anticancer Res. 2018-10

[9]
Retrospective Analysis of Radiological Recurrence Patterns in Glioblastoma, Their Prognostic Value And Association to Postoperative Infarct Volume.

Sci Rep. 2018-3-14

[10]
The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis.

J Neurosurg. 2018-1-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索